Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.

Helius Medical Technologies, Inc.

A neurotech company focused on neurologic deficits using non-implantable platform technologies that amplify the brain's ability to compensate and promote neuroplasticity, improving the lives of people dealing with neurologic diseases.

Helius Medical Technologies

Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brain’s ability to compensate and promotes neuroplasticity, aiming to improve the lives of people dealing with neurologic diseases. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS).

PoNS™, short for Portable Neuromodulation Stimulator, is an innovative medical device. It is inclusive of a controller and mouthpiece, that delivers mild stimulation to the surface of the tongue. This stimulation triggers a flow of neural impulses to the brain structures that control balance and gait. PoNS is meant to be used in conjunction with supervised therapeutic activity, referred to as, PoNS Therapy™. Use of the device while engaging in movement and coordination tasks promotes neuromodulation, activating brain pathways to help improve balance and gait.

PoNS is authorized in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (“MS”) and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.

PoNS is authorized in Canada for three indications: (i) for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used in conjunction with physical therapy; and (ii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy; and (iii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from stroke, to be used in conjunction with physical therapy. 

PoNS is authorized in Australia for short term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait.

PoNS™ (ponstherapy.com), short for Portable Neuromodulation Stimulator, is an innovative medical device. It is inclusive of a controller and mouthpiece, that delivers mild stimulation to the surface of the tongue. This stimulation triggers a flow of neural impulses to the brain structures that control balance and gait. PoNS is meant to be used in conjunction with supervised therapeutic activity, referred to as, PoNS Therapy™. Use of the device while engaging in movement and coordination tasks promotes neuromodulation, activating brain pathways to help improve balance and gait.

Studies have shown that individuals with multiple sclerosis who completed 14-weeks of PoNS Therapy® (www.ponstherapy.com) have seen improvements in their gait scores of an average of 8 points. 

An 8-point improvement in your gait can mean improving your walking so you can RSVP “yes” to the wedding, book the vacation you have been putting off, or go for a walk on the beach. 

Learn more at www.ponstherapy.com.

Individual results and experiences may vary. Speak to your physician to determine if PoNS is right for you.

After 14-weeks of PoNS Therapy® (www.ponstherapy.com), 100% of participants with multiple sclerosis saw a 
4-point improvement in dynamic gait index (DGI) scores, with an average of almost 8 points and 40% even saw improvements above 8 points. 

We encourage you to set your sights high – AIM FOR EIGHT points of improvement. 

Learn more: https://lnkd.in/e6Ja8tva

Individual results and experiences may vary. Speak to your physician to determine if PoNS® is right for you. 

#PoNS #PoNSTherapy #Helius #PortableNeuromodulationStimulator #physicaltherapy #GetBackInStepWithLife #MultipleSclerosis #MS #PhysicalRehabilitation #Walking

PoNS® (www.ponstherapy.com) is committed to improving walking ability across the country.  

Keep an eye out—we hope to bring PoNS to those in the US with gait deficit due to stroke soon.

Learn more: https://lnkd.in/eWPe7Tuy

#PoNS #PoNSTherapy #PoNSDevice #Helius #PortableNeuromodulationStimulator #physicaltherapy #GetBackInStepWithLife #MultipleSclerosis #MS #PhysicalRehabilitation #Walking #Stroke

PoNS® (www.ponstherapy.com) proudly supports our Veterans!

Discover how we're dedicated to helping Veterans with multiple sclerosis improve their gait on our new page. 

Learn more today: https://lnkd.in/eTb9Zfwf

#PoNS #PoNSTherapy #PoNSDevice #Helius #PortableNeuromodulationStimulator #GetBackInStepWithLife #PhysicalTherapy #MS #MultipleSclerosis #Veterans #VA #USVeterans #Vet

After using PoNS™ (www.ponstherapy.ca) for 14 weeks, 28% of people with stroke were no longer at fall risk. Routine physical therapy usually only provides a meaningful shift in fall risk for 1-3% of patients. 

Learn more about PoNS Therapy™: www.ponstherapy.ca

Individual results and experiences vary. Patients should talk to their doctor to see if PoNS is right for them. 


#PoNS #PoNSTherapy #PoNSDevice #Helius #PortableNeuromodulationStimulator #physicaltherapy #GetBackInStepWithLife #TraumaticBrainInjury #TBI #Stroke #MultipleSclerosis #MS #PhysicalRehabilitation #Walking #Neurostimulation #FallRisk

	Mar '14	Mar '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-1.07M -	-8.89M 733.38%	-12.04M 35.36%	-28.02M 132.76%	-28.62M 2.14%	-9.78M 65.83%	-14.13M 44.46%	-18.13M 28.32%	-14.07M 22.39%	-8.85M 37.11%
depreciation and amortization				17K -	59K 247.06%	191K 223.73%	482K 152.36%	312K 35.27%	255K 18.27%	45K 82.35%
deferred income tax							453K -	-29K 106.40%
stock based compensation	807.16K -	1.40M 73.09%	1.46M 4.64%	1.82M 24.35%	8.10M 345.27%	4.69M 42.05%	2.53M 46.09%	4.25M 68.13%	2.25M 46.99%	1.63M 27.73%
change in working capital	-89.92K -	260.29K 389.49%	854K 228.09%	1.84M 114.99%	-1.02M 155.45%	-2.28M 123.67%	-1.02M 55.38%	127K 112.50%	-1.31M 1,128.35%	-10K 99.23%
accounts receivables		-8.95K -	174K 2,045.22%	-479K 375.29%	429K 189.56%	-438K 202.10%	-4K 99.09%	30K 850%	-9K 130%	-44K 388.89%
inventory		-110.87K -			-392K -	-206K 47.45%	4K 101.94%	-87K 2,275%	-111K 27.59%	137K 223.42%
accounts payables	210.09K -	979.04K 366.02%	345K 64.76%	1.32M 282.03%	-1.09M 182.47%	-1.12M 2.67%	-635K 43.10%	369K 158.11%	-418K 213.28%	-103K 75.36%
other working capital	-300K -	-598.93K 99.64%	335K 155.93%	997K 197.61%	32K 96.79%	-517K 1,715.63%	-381K 26.31%	-185K 51.44%	-768K 315.14%	10K 101.30%
other non cash items	1.34K -	915.86K 68,044.57%	1.84M 100.79%	5.03M 173.41%	1.87M 62.89%	-13.82M 840.78%	-56K 99.59%	82K 246.43%	-1.44M 1,857.32%	-3.24M 124.84%
net cash provided by operating activities	-348.70K -	-6.32M 1,712.83%	-7.88M 24.74%	-19.32M 145.09%	-19.62M 1.53%	-21.00M 7.02%	-11.74M 44.10%	-13.39M 14.06%	-14.31M 6.89%	-10.42M 27.21%
investments in property plant and equipment				-190K -	-440K 131.58%	-353K 19.77%	-70K 80.17%	-56K 20%	-17K 69.64%	-29K 70.59%
acquisitions net						-416K -	61K 114.66%		6K -
purchases of investments		-378K -
sales maturities of investments
other investing activites			378B -
net cash used for investing activites		-378K -	378B 100,000,100%	-190K 100.00%	-440K 131.58%	-769K 74.77%	-9K 98.83%	-56K 522.22%	-11K 80.36%	-29K 163.64%
debt repayment	-2.23K -						-323K -
common stock issued		7.06M -	7.90M 12.00%	20.88M 164.18%	38.53M 84.53%	1.69M 95.63%	10.65M 532.23%	22.70M 113.04%	18.64M 17.85%	500K 97.32%
common stock repurchased
dividends paid
other financing activites	366.68K -	426.17K 16.23%	94K 77.94%	1.34M 1,325.53%	1.50M 12.09%	-32K 102.13%	-692K 2,062.50%	-1.57M 126.73%	-775K 50.61%	577K 174.45%
net cash used provided by financing activities	364.45K -	7.48M 1,953.16%	8.00M 6.87%	22.22M 177.83%	40.03M 80.16%	1.65M 95.87%	9.64M 483.06%	21.13M 119.19%	17.87M 15.42%	1.08M 93.97%
effect of forex changes on cash		-380.52K -	-87K 77.14%	190K 318.39%	54K 71.58%	-9K 116.67%	-19K 111.11%	-8K 57.89%	-4K 50%	1K 125%
net change in cash	15.75K -	402.93K 2,458.09%	25K 93.80%	2.89M 11,472%	20.02M 592.05%	-20.12M 200.51%	-2.13M 89.43%	7.67M 460.62%	3.54M 53.82%	-9.37M 364.31%
cash at beginning of period	217 -	15.97K 7,258.53%	2.64M 16,458.12%	2.67M 0.95%	5.56M 108.39%	25.58M 359.96%	5.46M 78.66%	3.33M 38.98%	11.01M 230.38%	14.55M 32.20%
cash at end of period	15.97K -	418.89K 2,523.33%	2.67M 537.16%	5.56M 108.39%	25.58M 359.96%	5.46M 78.66%	3.33M 38.98%	11.01M 230.38%	14.55M 32.20%	5.18M 64.38%
operating cash flow	-348.70K -	-6.32M 1,712.83%	-7.88M 24.74%	-19.32M 145.09%	-19.62M 1.53%	-21.00M 7.02%	-11.74M 44.10%	-13.39M 14.06%	-14.31M 6.89%	-10.42M 27.21%
capital expenditure				-190K -	-440K 131.58%	-353K 19.77%	-70K 80.17%	-56K 20%	-17K 69.64%	-29K 70.59%
free cash flow	-348.70K -	-6.32M 1,712.83%	-7.88M 24.74%	-19.52M 147.50%	-20.06M 2.80%	-21.35M 6.44%	-11.81M 44.70%	-13.44M 13.86%	-14.33M 6.57%	-10.45M 27.10%

COM:HELIUSMEDICAL

Helius Medical Technologies

Last Close

0.47

21/11 21:00

Market Cap

2.54M

Beta: -

Volume Today

57.45K

Avg: -

Preview